Overview

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Status:
Not yet recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Collaborator:

Peking Union Medical College Hospital

Treatments:

Letrozole
Medroxyprogesterone
Medroxyprogesterone Acetate
Megestrol
Megestrol Acetate